Extracorporeal photopheresis (ECP) was the first therapy approved by the Food and Drug Administration (FDA) specifically for the treatment of cutaneous T-cell lymphoma. ECP may be an effective treatment for CTCL that has not responded to other types of therapy.
ECP is an immunotherapy approved for cutaneous T-cell lymphoma and recommended for patients with blood involvement. That is, CTCL cells detected in the blood (Sezary Syndrome and Stage III Erythrodermic MF).
